Autopsy report · NCT07489560

Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns

“Change in company strategy.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Cellution Biologics

Sponsor type

Industry

Conditions

Partial Thickness Burn

Interventions

Amnion-Intermediate-Chorion; Standard of Care (SOC)

Participants

0

Trials that died the same way

• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (84% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (83% match in meaning)
• Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
  “Company Strategy” (83% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (82% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.